A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS222, which is an Antibody medication, in Subjects with Advanced Malignancies

2024-514010-12-00 Protocol FS222-19101 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 3 Dec 2020 · Status Ongoing, recruiting · 5 EU/EEA countries · 25 sites · Protocol FS222-19101

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 361
Countries 5
Sites 25

Advanced Malignancies

Key facts

Sponsor
Invox Pharma Limited
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
3 Dec 2020 → ongoing
Decision date (initial)
2025-03-28
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-514010-12-00
EudraCT number
2020-003021-28
ClinicalTrials.gov
NCT04740424

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced Malignancies

VersionLevelCodeTermSystem organ class
21.0 LLT 10048683 Advanced cancer 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Invox Pharma Limited

Sponsor organisation
Invox Pharma Limited
Address
Suite 2, First Floor Westworks Wood Lane, White City Place First Floor Westworks Wood Lane White City Place
City
London
Postcode
W12 7FQ
Country
United Kingdom

Scientific contact point

Organisation
Invox Pharma Limited
Contact name
invoX Pharma Clinical Trials

Public contact point

Organisation
Invox Pharma Limited
Contact name
invoX Pharma Clinical Trials

Locations

5 EU/EEA countries · 25 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ongoing, recruiting 30 4
Netherlands Ongoing, recruiting 12 3
Poland Ongoing, recruiting 12 4
Romania Ongoing, recruiting 35 2
Spain Ongoing, recruiting 234 12
Rest of world
Georgia, Australia
38

Investigational sites

Germany

4 sites · Ongoing, recruiting
Universitaetsklinikum Essen AöR
Klinik für Dermatologie, Venerologie und Allergologie, Hufelandstrasse 55, Holsterhausen, Essen
SLK-Kliniken Heilbronn GmbH
Klinikum am Gesundbrunnen, Am Gesundbrunnen 20-26, Neckargartach, Heilbronn
Charite Universitaetsmedizin Berlin KöR
Early Clinical Trial Unit (ECTU), Hindenburgdamm 30, Lichterfelde, Berlin
Technische Universitaet Dresden
Medizinische Fakultät Carl Gustav Carus Nationales Centrum für Tumorerkrankungen Dresden (NCT/UCC), Fetscherstrasse 74, Johannstadt-Nord, Dresden

Netherlands

3 sites · Ongoing, recruiting
Radboud universitair medisch centrum Stichting
Medische Oncologie, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Medische Oncologie, Plesmanlaan 121, 1066 CX, Amsterdam
Leids Universitair Medisch Centrum (LUMC)
Medische Oncologie, Albinusdreef 2, 2333 ZA, Leiden

Poland

4 sites · Ongoing, recruiting
Biokinetica S.A.
n/a, Ul. Nadwislanska 37, 05-410, Jozefow
Pratia S.A.
n/a, Ul. Pana Tadeusza 2, 30-727, Cracow
Pratia Hematologia Sp. z o.o.
n/a, Ul. Tadeusza Kosciuszki 92, 40-519, Katowice
Pratia S.A.
n/a, Ul. Gryfinska 1, 60-192, Poznan

Romania

2 sites · Ongoing, recruiting
Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca
Phase 1 Unit, Radiotherapy, Strada Republicii 34-36, 400015, Cluj-Napoca
Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti
Phase 1 Unit, Medical Oncology II, Radiotherapy I, Soseaua Fundeni 252, 022328, Bucharest

Spain

12 sites · Ongoing, recruiting
Clinica Universidad De Navarra
Medical Oncology Department, Avenue Pio XII 36, 31008, Pamplona
Hospital Clinic De Barcelona
Medical Oncology Department, Calle Villarroel 170, 08036, Barcelona
Complejo Hospitalario Universitario Insular Materno Infantil
Medical Oncology Department, Autovia Del Sur S/n, 35017, Las Palmas De Gran Canaria
Hospital Clinico Universitario De Valencia
Medical Oncology Department, Avenida Blasco Ibanez 17, 46010, Valencia
Hospital Universitario Quironsalud Madrid
Medical Oncology Department, Calle De Diego De Velazquez 1, 28223, Pozuelo De Alarcon
Hospital Universitario Fundacion Jimenez Diaz
Medical Oncology Department, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Universitario Puerta De Hierro De Majadahonda
Medical Oncology Department, Calle De Joaquin Rodrigo 2, 28222, Majadahonda
Institut Catala D'oncologia
Medical Oncology Department, Carretera Canyet S/n, 08916, Badalona
Hospital Universitario Virgen De La Macarena
Medical Oncology Department, Avenida Del Doctor Fedriani 3, 41009, Sevilla
Hospital Universitari Vall D Hebron
Medical Oncology Department, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Quironsalud Barcelona
Medical Oncology Department, Placa D'alfonso Comin 5-7, 08023, Barcelona
Hospital Universitario 12 De Octubre
Medical Oncology Department, Bloque D, Avenida De Cordoba Sn, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2025-06-25 2025-07-10
Netherlands 2025-05-27 2025-06-11
Poland 2025-05-06 2025-05-14
Romania 2022-12-12 2023-08-02
Spain 2020-12-03 2020-12-29

Application history

7 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-05-29 Spain Acceptable
2024-06-17
2024-06-17
2 SUBSTANTIAL MODIFICATION SM-1 2024-09-06 Spain Acceptable
2024-11-07
2024-11-07
3 SUBSEQUENT ADDITION OF MSC APP-3 2025-01-08 2025-04-02
4 SUBSEQUENT ADDITION OF MSC APP-4 2025-01-09 Acceptable
2024-11-07
2025-03-28
5 SUBSTANTIAL MODIFICATION SM-2 2025-01-09 Spain Acceptable 2025-02-11
6 SUBSEQUENT ADDITION OF MSC APP-6 2025-01-10 Acceptable
2024-11-07
2025-04-06
7 SUBSTANTIAL MODIFICATION SM-3 2025-11-19 Spain Acceptable
2026-02-25
2026-02-26